PaxMedica, Inc. (PXMD)
PaxMedica will go public soon, but the exact IPO date is still unknown.
Stock Price: $5.50 - $6.50
Current IPO price range
| Market Cap | 59.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.15M |
| Shares Out | 9.98M |
| EPS (ttm) | -0.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | $n/a |
| Previous Close | $n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a - n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a - n/a |
News
There are no news available yet.
About PXMD
PaxMedica is an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). Antipurinergic therapies target the excess production of purines in cells, which can offset homeostasis and result in an overproduction of cellular adenosine triphosphate (or ATP), the main energy molecule in all living cells.
| CEO Howard J. Weisman | Employees 4 |
| Stock Exchange NASDAQ | Ticker Symbol PXMD |